nonrecommended AVF was created (AVG, 36; AVF, 17). Excluded were 25 patients who were lost to follow-up, died early, or never started dialysis. The functional maturation rate for AVF recommended by the VAPS was 78% (matured, 75; failed, 21). At least one intervention was required in 29% (22 of 75) of matured fistulas required to achieve maturation. The maturation rate for AVF not recommended by the VAPS was 62% (matured, 8; failed, 5).
VESS15.

Association of Variant Arch
Objectives: Aortic arch embryologic variations are more common in patients with thoracic aortic disease for reasons unknown. Additionally, little is understood about their relation to type B dissections (TBAD) specifically. We investigated the prevalence of variant aortic arches in patients with TBAD compared to controls. In order to understand the implications of a variant aortic arch anatomy to degenerative aortic disease, we compared flow hemodynamics of three variations of aortic arches using four-dimensional (4D) flow magnetic resonance imaging (4D Flow MRI).
Methods: A cohort of patients with TBAD was age/gender matched with controls free of aortic pathology. Arch variants were defined and assessed: common origin of innominate and left common carotid artery (bovine arch and truncus bicaroticus), aberrant right subclavian artery (SCA), and right-sided aortic arch. Demographics and TBAD characteristics were abstracted, and TBAD patients with variant and conventional aortic arches were compared. Additionally, three matched healthy controls with conventional, bovine, and aberrant right SCA arches underwent 4D flow MRI evaluation. Indices of regional hemodynamic wall sheer stress (WSS) were compared (systolic WSS, time-averaged WSS [TA-WSS], and oscillatory shear index [OSI]).
Results: Computed tomography scans of 185 consecutive TBAD patients (72.4% males, 71% Caucasian) and 367 controls (67% males, 78% Caucasian) were reviewed. Variant arch anatomy was significantly more prevalent in TBAD patients (39.5% vs 22.6%; P < .0001). Among those with TBAD, the mean age of presentation and descending thoracic aorta (DTA) diameter were similar whether they had variant or conventional aortic arches (Table) . The most common arch variant was the bovine arch (37.3% vs 22.3% controls; P < .0001) and was associated with a higher prevalence of dissection entry tears proximal to the left SCA (12.7% vs 6.6% distal; P ¼ .178). 4D flow MRI demonstrated hemodynamic variations between arch types: The bovine arch had the highest systolic WSS along the inner curve, TA-WSS in zone 1, and OSI in zone 2 (Fig) . The conventional arch had the lowest TA-WSS, while the aberrant RSCA arch had the lowest OSI.
Conclusions: Variant aortic arch anatomy is significantly more prevalent in TBAD patients in this predominantly Caucasian population. The bovine arch demonstrated hemodynamic flow alterations typically associated with endothelial injury and vascular stiffness. This could potentially explain the higher prevalence of variant arch anatomy in TBAD patients. Studies of long-term outcomes based on arch anatomy and 4D flow MRI in TBAD will offer additional insight to TBAD genesis and may influence management decisions.
Author Disclosures: F. Bolster: Nothing to disclose; T. Hatsukami: Nothing to disclose; O. Jazaeri: Nothing to disclose; J. J. Reynolds: Nothing to disclose; M. Schafer: Nothing to disclose; S. Shalhub: Nothing to disclose; N. Singh: Nothing to disclose; B. W. Starnes: AORTICA Corporation: intellectual property/patents, ownership interest; M. P. Sweet: Nothing to disclose. 
VESS16.
Study to Assess Outcomes for Multiple TEVAR Pathologies (SUMMIT) Registry
Cook Research Incorporated
Objectives: Thoracic endovascular aortic repair (TEVAR) is currently the treatment of choice for most pathologies of the descending thoracic aorta. Using data from the Cook SUMMIT registry, we aim to investigate the outcomes of TEVAR for the treatment of different pathologies within instructions for use (IFU) and understand predictive factors affecting outcomes.
Methods: The SUMMIT registry includes aggregated data of 521 TEVAR patients from five prospective, multicenter trials evaluating thoracic endografts of the Zenith platform (Cook Medical, Bloomington, Ind): 
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